Sander J. H. Van Deventer
#186,988
Most Influential Person Now
Sander J. H. Van Deventer's AcademicInfluence.com Rankings
Sander J. H. Van Deventerphilosophy Degrees
Philosophy
#12161
World Rank
#16852
Historical Rank
Logic
#8975
World Rank
#11311
Historical Rank
Download Badge
Philosophy
Sander J. H. Van Deventer's Degrees
- Masters Medicine University of Amsterdam
- PhD Medicine University of Amsterdam
Why Is Sander J. H. Van Deventer Influential?
(Suggest an Edit or Addition)Sander J. H. Van Deventer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease (1997) (2858)
- Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations (2001) (1126)
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial (2008) (929)
- Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease (2000) (424)
- Tumour necrosis factor and Crohn's disease. (1997) (299)
- Effect of preoperative oral immune-enhancing nutritional supplement on patients at high risk of infection after cardiac surgery: a randomised placebo-controlled trial (2001) (195)
- Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial (2015) (159)
- Transmembrane TNF-α, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn's disease (2001) (115)
- IL-10 gene therapy prevents TNBS-induced colitis (2002) (81)
- Dichotomy between Lactobacillus rhamnosus and Klebsiella pneumoniae on dendritic cell phenotype and function (2004) (80)
- Cytokine and cytokine receptor polymorphisms in infectious disease (2000) (80)
- Review article: targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease--the mechanisms of action of infliximab. (1999) (76)
- Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn’s disease patients (2005) (67)
- Immunotherapy of Crohn's Disease (2000) (34)
- Small therapeutic molecules for the treatment of inflammatory bowel disease (2002) (31)
- Anti-TNF antibody treatment of Crohn's disease. (1999) (29)
- A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2) (2004) (24)
- Intrastriatal Administration of AAV5-miHTT in Non-Human Primates and Rats Is Well Tolerated and Results in miHTT Transgene Expression in Key Areas of Huntington Disease Pathology (2021) (19)
- Induction of Antigen-Specific Tolerance by Oral Administration of Lactococcus lactis Delivered Immunodominant DQ8-Restricted Gliadin Peptide in Sensitized Nonobese Diabetic Ab Dq8 Transgenic Mice (2009) (18)
- New biological therapies in inflammatory bowel disease. (2003) (15)
- Anti-TNF antibody cA2 induces apoptosis in CD3/CD28 stimulated Jurkat cells: a potent immunomodulating mechanism (1999) (15)
- Anti- and proinflammatory effects of interleukin-10 in mild to moderate Crohn's disease (1999) (12)
- escalating dose study of alicaforsen enema in active ulcerative colitis (2004) (11)
- Meningococcal disease: A comparison of eight severity scores in 125 children (1996) (10)
- Immunomodulation of Crohn's disease using TNF-αneutralizing monoclonal antibodies* (1997) (7)
- Anti-tumour necrosis factor therapy in Crohn's disease: where are we now? (2002) (7)
- Taming the mucosal immune response in Crohn's disease (2002) (7)
- Severe Crohn's Disease Semapimod Induces Clinical Remission in Specific Inhibition of c-Raf Activity by (2005) (6)
- Immunomodulation of Crohns Disease (2000) (6)
- Immunomodulation of Crohn's Disease. (2000) (5)
- Immunosuppression Modulates Immune Responses to AAV Capsid in Human Subjects Undergoing Intramuscular Gene Transfer for Lipoprotein Lipase Deficiency (2008) (5)
- Seroprevalence of Pre-Existing Nabs Against AAV1, 2, 5, 6 and 8 in South African Hemophilia B Patient Population (2019) (4)
- Basic fibroblast growth factor (BFGF) as a response parameter to infliximab (Remicade)in fistulizing Crohn's disease (2003) (3)
- Safety and Efficacy of Recombinant Human Interleukin 10 in Chronic Active Crohn’s Disease (2000) (3)
- Inflammatory bowel disease: Future therapies (2002) (2)
- Optimizing Outcomes in Hepatitis C: Is Treatment Beyond 48 Weeks Ever Justified? (2006) (2)
- Cytokine Induction in Experimental and Ulcerative Colitis (1992) (2)
- The future of inflammatory bowel disease therapy. (2002) (2)
- Cytokines and cytokine-based therapies (1998) (2)
- Cytokines and Mucosal Inflammatory Response in Crohn's Disease (2003) (2)
- Abstract 2093: AAV1-LPLS447X Gene Therapy With Alipogene Tiparvovec Prevents Pancreatitis in Lipoprotein Lipase Deficiency (2009) (2)
- Genomics of the Sepsis Syndrome (2002) (2)
- Abstract: 554 AN OPEN-LABEL, DOSE ESCALATION STUDY TO ASSESS THE SAFETY AND EFFICACY OF AAV1-LPLS447X GENE THERAPY WITH ALIPOGENE TIPARVOVEC (AMT-011) FOR PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA DUE TO LIPOPROTEIN LIPASE DEFICIENCY (LPLD) (2009) (1)
- Inhibitor of TGF-Regulatory T Cell Activity with a Peptide In Vitro and In Vivo Down-Regulation of Borrás (2008) (1)
- I05 Sustained mutant huntingtin lowering in the brain and cerebrospinal fluid of huntington disease minipigs mediated by AAV5-MIHTT gene therapy (2018) (1)
- EFFICACY ASSESSMENT OF NATALIZUMAB IN PATIENTS WITH CROHNʼS DISEASE AND PRIOR HISTORY OF INFLIXIMAB THERAPY: 831 (2004) (1)
- Induction of antigen-specific oral tolerance by genetically modified Lactococcus lactis delivering DQ8-specific immunodominant gliadin epitopes to gluten-sensitized class II transgenic mice (2007) (1)
- Abstract 1497: Enhanced atherogenesis and altered High Density Lipoprotein in patients with Crohn's Disease (2006) (1)
- Natalizumab induces and maintains continuous response and remission in patients with active Crohnʼs disease despite prior anti-tumor necrosis factor-alpha treatment: O-033. (2008) (1)
- Natalizumab Improves the Health Related Quality of Life (HRQOL) in Crohnʼs Disease Patients: 842 (2005) (1)
- Infliximab does not result in increased, abscess development in fistulizing Crohn's disease: Results from ACCENT II (2003) (1)
- THU-363-Lipid nanoparticle pre-treatment improves adeno-associated virus diffusion in the primate liver and enables an increase of therapeutic transgene expression (2019) (0)
- Alipogene Tiparvovec Development: An Example of an Application of Gene Therapy Application Possibilities (2010) (0)
- Therapeutic agents of alanine glyoxylate aminotransferase (2010) (0)
- Intravenous pamidronate in combination with calcium and vitamin D is highly effective for the treatment of low bone mineral density in Crohns disease (2003) (0)
- Methotrexate therapy for Crohns disease: long-term efficacy and safety (2003) (0)
- Therapeutic expression of hairpins targeting Apolipoprotein B100 induces differential changes in murine liver (2013) (0)
- I04 AAV5-MIHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a huntington disease minipig model (2018) (0)
- Identification of an IBD associated haplotype on BACs A-249810 and 504N19 on proximal chromosome 16p (2001) (0)
- Characterization of a putative human immunoregulatory protein : the role of Tj 6 an [ H + ] $ ATPase $ like protein in lymphocyte activation (2003) (0)
- Up-Regulated During Active Crohn's Disease Endothelial Cells and Macrophages Is IL-18-Binding Protein Expression by (2013) (0)
- Immune modulation of Crohn's disease: clinical studies (1997) (0)
- Patients with Mild Disease May Contribute to a High Placebo Response Rate in Ulcerative Colitis Studies, Resulting in Noise That May Obscure Endpoint Detection: 799 (2005) (0)
- THERAPEUTIC MICRORNAS TARGETING NUCLEAR HUNTINGTIN FOR A DEVELOPMENT OF A PERSONALIZED GENE THERAPY FOR HUNTINGTON’S DISEASE (2019) (0)
- Induction of IL-8 in Inflammatory Bowel Disease (1993) (0)
- Nod2 is expressed by myeloid blood dendritic cells, mature Nod2 mutant and wild-type blood dendritic cells induce similar T-cell phenotypes (2003) (0)
- Development of an AAV5-based gene therapy for Fabry disease (2020) (0)
- Genomics of the spesis syndrome (1999) (0)
- UvA-DARE ( Digital Academic Repository ) In vivo signal transduction : mitogen activated protein kinases in inflammation (2007) (0)
- I06 Efficacy and safety of AAV5-MIHTT in hd patient-derived neurons (2018) (0)
- Late Breaking Abstracts Submitted to DDW These Abstracts Were Submitted to the AGA in mid-March, Selected by the AGA Council, and Presented During DDW 2004 in New Orleans, Louisiana. (2004) (0)
- Native low density lipoprotein induces transition of monocytic cell lines into foam cell-like cell lines (1995) (0)
- Inhibition of tumour necrosis factor α converting enzyme as a new therapeutic target in inflammatory bowel disease (2002) (0)
- Abstract: P475 SAFETY AND EFFICACY OF AMT-010 GENE THERAPY IN LIPOPROTEIN LIPASE DEFICIENCY (LPLD) (2009) (0)
- Induction of OVA-specific tolerance by oral administration of Lactococcus lactis secreting OVA (2009) (0)
- Influence of the number of kringle IV repeats in apolipoprotein ( a ) on Lipoprotein ( a ) quantification by four commercial available assays (1999) (0)
- M1738 The Genetically Modified Lactococcus Lactis Ova Modulates T-Cells Through an Antigen-Specific Effect on Dendritic Cells (2010) (0)
- L5 Pre-clinical evaluation of aav5-mihtt gene therapy of huntington’s disease in rodents (2016) (0)
- Targeted therapies for inflammatory bowel disease (2003) (0)
- Interleukin 10 gene therapy for Crohn ' s disease (2007) (0)
- Is budesonide an advance in the treatment of Crohn's disease? (2001) (0)
- Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4 (cid:1) T cells via modulation of dendritic cell function 1–3 (2004) (0)
- EFFICACY, SAFETY, AND TOLERABILITY OF NATALIZUMAB IN MAINTAINING CLINICAL RESPONSE AND REMISSION IN CROHNʼS DISEASE (ENACT-2): 788 (2004) (0)
- Distinct effects of Lactobacillus rhamnosus and Klebsiella pneumoniae on final dendritic cell function (2003) (0)
This paper list is powered by the following services:
